Lindbrook Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,032
| Closed | -$3.14K | – | 2964 |
|
|
2024
Q4 | $3.14K | Buy |
1,032
+398
| +63% | +$1.73K | ﹤0.01% | 2161 |
|
|
2024
Q3 | $3.29K | Hold |
634
| – | – | ﹤0.01% | 2180 |
|
|
2024
Q2 | $1.63K | Buy |
634
+546
| +620% | +$1.86K | ﹤0.01% | 2403 |
|
|
2024
Q1 | $433 | Sell |
88
-35
| -28% | -$207 | ﹤0.01% | 2531 |
|
|
2023
Q4 | $1.08K | Sell |
123
-151
| -55% | -$1.24K | ﹤0.01% | 2448 |
|
|
2023
Q3 | $3.14K | Buy |
274
+143
| +109% | +$2.75K | ﹤0.01% | 1964 |
|
|
2023
Q2 | $3.32K | Hold |
131
| – | – | ﹤0.01% | 1974 |
|
|
2023
Q1 | $4.22K | Sell |
131
-60
| -31% | -$1.87K | ﹤0.01% | 1920 |
|
|
2022
Q4 | $3.53K | Hold |
191
| – | – | ﹤0.01% | 1982 |
|
|
2022
Q3 | $5K | Buy |
191
+30
| +19% | +$609 | ﹤0.01% | 1707 |
|
|
2022
Q2 | $2K | Hold |
161
| – | – | ﹤0.01% | 2089 |
|
|
2022
Q1 | $3K | Buy |
161
+37
| +30% | +$561 | ﹤0.01% | 1902 |
|
|
2021
Q4 | $2K | Buy |
124
+36
| +41% | +$600 | ﹤0.01% | 1843 |
|
|
2021
Q3 | $2K | Hold |
88
| – | – | ﹤0.01% | 1638 |
|
|
2021
Q2 | $3K | Hold |
88
| – | – | ﹤0.01% | 1524 |
|
|
2021
Q1 | $2K | Hold |
88
| – | – | ﹤0.01% | 1631 |
|
|
2020
Q4 | $2K | Buy |
+88
| New | +$2.28K | ﹤0.01% | 1533 |
|
Other funds holding RVNC
Lindbrook Capital's RVNC Position: Q1 2025 in Review
Lindbrook Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,032 shares — an estimated $3.14K sold.
Lindbrook Capital first reported a position in RVNC in Q4 2020 and held it in 17 quarters. The position peaked at $5K in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Lindbrook Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Lindbrook Capital sold 1,032 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $3.14K.
- Lindbrook Capital first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 17 quarters.
- Lindbrook Capital's Revance Therapeutics, Inc. position peaked at $5K in Q3 2022.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.